MS Proteotyping of Human Cancers in Oncology Therapeutic Development

Supported by Thermo Fisher Scientific


In this workshop, our customer and collaborator, Dr. Dan Liebler, President of Protypia, Inc., will highlight his research on MS proteotyping of human cancers in oncology therapeutic development using Thermo Scientific Orbitrap technology.

New therapeutics targeting immune checkpoint proteins have significantly advanced treatment of non-small cell lung cancer (NSCLC), but protein level quantitation of drug targets presents a critical problem.

Dr. Liebler focuses on his use of multiplexed, targeted mass spectrometry (MS) to quantify immunotherapy target proteins PD-1, PD-L1, PD-L2, IDO1, LAG3, TIM3, ICOSLG, VISTA, GITR, and CD40 in formalin-fixed, paraffin-embedded (FFPE) NSCLC specimens. Global proteome analyses identified distinct proteotypes associated with high PD-L1-expressing and high IDO1-expressing NSCLC.

Find out how MS quantification of multiple drug targets and tissue proteotypes can improve clinical evaluation of immunotherapies for NSCLC.

Who Should Attend

Clinical researchers interested in learning about the use of Orbitrap mass spectrometry for protein quantitation.


Attendees will learn:

  • How to overcome inherent challenges in protein quantitation of drug targets
  • How to use multiplexed mass spectrometry to quantify target proteins
  • How MS quantification can improve evaluation of immunotherapies


Daniel C. Liebler, PhD
Protypia, Inc.
Nashville, Tennessee